An Overview of the Current Development of Phytoremedies for Breast Cancer

Lin, Chun‐Hung; Lee, Wai Leng; Shyur, Lie‐Fen

doi:10.1007/978-94-007-1983-5_3

Cited by 4 publications

(1 citation statement)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identification and validation of the potential benefits of phytocompounds with low toxicity but effective for cancer inhibition has thus become an important area of pharmaceutical science (Newman and Cragg, 2007). The pressing need for development of new therapeutic or preventive agents for cancer diseases has spurred the search for bioactive phytocompounds or their derived analogues with novel modes of action or improved efficacy (Lin et al., 2012; Newman and Cragg, 2007; Pan et al., 2010). To investigate whether DETD‐35 acts synergistically with PTX against MDA‐MB‐231 cell activity, anti‐proliferation assay using MTT reagent was first performed to obtain IC values of each compound.…”

Section: Resultsmentioning

confidence: 99%

Novel sesquiterpene lactone analogues as potent anti‐breast cancer agents

et al. 2016

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is associated with high grade, metastatic phenotype, younger patient age, and poor prognosis. The discovery of an effective anti-TNBC agent has been a challenge in oncology. In this study, fifty-eight ester derivatives (DETDs) with a novel sesquiterpene dilactone skeleton were organically synthesized from a bioactive natural product deoxyelephantopin (DET). Among them, DETD-35 showed potent antiproliferative activities against a panel of breast cancer cell lines including TNBC cell line MDA-MB-231, without inhibiting normal mammary cells M10. DETD-35 exhibited a better effect than parental DET on inhibiting migration, invasion, and motility of MDA-MB-231 cells in a concentration-dependent manner. Comparative study of DETD-35, DET and chemotherapeutic drug paclitaxel (PTX) showed that PTX mainly caused a typical time-dependent G2/M cell-cycle arrest, while DETD-35 or DET treatment induced cell apoptosis. In vivo efficacy of DETD-35 was evaluated using a lung metastatic MDA-MB-231 xenograft mouse model. DETD-35 significantly suppressed metastatic pulmonary foci information along with the expression level of VEGF and COX-2 in SCID mice. DETD-35 also showed a synergistic antitumor effect with PTX in vitro and in vivo. This study suggests that the novel compound DETD-35 may have a potential to be further developed into a therapeutic or adjuvant agent for chemotherapy against metastatic TNBC.

show abstract

Section: Resultsmentioning

confidence: 99%